Menu
Peptide Database
Results
No peptides found
Featured

Use search to browse all 100+ peptides

P021

Peptide 021, GLXC-21260

Quick Stats
Studies 37
Trials 57
Score 1
2002 pubmed

Age-dependency of analgesia elicited by intraoral sucrose in acute and persistent pain models.

Anseloni. Vanessa C Z VC; Weng. H-R HR; Terayama. R R; Letizia. David D; Davis. Barry J BJ; Ren. Ke K; Dubner. Ronald R; Ennis. Matthew M

Key Findings

  • Intra‑oral sucrose reduces pain responses in newborn rats, starting around day 3, peaking around days 7‑10, and gone by day 17.
  • The analgesic effect appears later for hindpaw (around day 13) than forepaw stimuli.
  • In inflamed (CFA‑treated) rats, sucrose also lessens heightened pain (hyperalgesia), with a similar age window.

Practical Outcomes

  • For adult biohackers, this study suggests sweet solutions are not a reliable pain‑killer beyond early infancy. The findings mainly support using sucrose for neonatal pain management in clinical settings, not for general longevity or performance protocols.

Summary

In baby rats, giving a sweet sugar solution by mouth can temporarily dull pain from heat or pressure, but this effect only shows up in the first few weeks after birth and disappears by about three weeks old. The pain‑relief works a bit better when the rats have inflamed paws, and the timing of the effect differs slightly between front and back paws.

Abstract

Treatment of pain in newborns is associated with problematic drug side effects. Previous studies demonstrate that an intraoral infusion of sucrose and other sweet components of mother's milk are effective in alleviating pain in infant rats and humans. These findings are of considerable significance, as sweet tastants are used in pain and stress management in a number of clinical procedures performed in human infants. The ability of sweet stimuli to induce analgesia is absent in adult rats, suggesting that this is a developmentally transient phenomenon. However, the age range over which intraoral sucrose is capable of producing analgesia is not known. We investigated the effects of intraoral sucrose (7.5%) on nocifensive withdrawal responses to thermal and mechanical stimuli in naive and inflamed rats at postnatal days (P) P0-21. In some rats, Complete Freund's adjuvant (CFA) was injected in a fore- or hindpaw to produce inflammation. In non-inflamed animals, for noxious thermal stimuli, sucrose-induced analgesia emerged at P3, peaked at P7-10, then progressively declined and was absent at P17. For mechanical forepaw stimuli, sucrose-induced analgesia emerged, and was maximal at approximately P10, then declined and was absent at P17. By contrast, maximal sucrose-induced analgesia for mechanical hindpaw stimuli was delayed (P13) compared to that for the forepaw, although it was also absent at P17. In inflamed animals, sucrose reduced hyperesthesia and hyperalgesia assessed with mechanical stimuli. Sucrose-induced analgesia in inflamed animals was initially present at P3 for the forepaw and P13 for the hindpaw, and was absent by P17 for both limbs. Intraoral sucrose produced significantly greater effects on responses in fore- and hindpaws in inflamed rats than in naive rats indicating that it reduces hyperalgesia and allodynia beyond its effects on responses in naive animals. These findings support the hypothesis that sucrose has a selective influence on analgesic mechanisms and that an enhanced sucrose effect takes place in hyperalgesic, inflamed animals as compared to naive animals. Taken together, these results indicate that intraoral sucrose alleviates transient pain in response to thermal and mechanical stimuli, and also effectively reduces inflammatory hyperalgesia and allodynia. Sucrose-induced analgesia is age-dependent and limited to the pre-weaning period in rats. The age-dependency of sucrose-induced analgesia and its differential maturation for the fore- and hindpaw may be due to developmental changes in endogenous analgesic mechanisms and developmental modulation of the interaction between gustatory and pain modulatory pathways.

Study Information

Provider

pubmed

Year

2002

DOI

10.1016/s0304-3959(02)00010-6